4FIE

Full-length human PAK4


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.11 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.256 
  • R-Value Observed: 0.257 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.

Ha, B.H.Davis, M.J.Chen, C.Lou, H.J.Gao, J.Zhang, R.Krauthammer, M.Halaban, R.Schlessinger, J.Turk, B.E.Boggon, T.J.

(2012) Proc Natl Acad Sci U S A 109: 16107-16112

  • DOI: 10.1073/pnas.1214447109
  • Primary Citation of Related Structures:  
    4FIG, 4FIH, 4FII, 4FIJ, 4FIE, 4FIF

  • PubMed Abstract: 
  • The type II p21-activated kinases (PAKs) are key effectors of RHO-family GTPases involved in cell motility, survival, and proliferation. Using a structure-guided approach, we discovered that type II PAKs are regulated by an N-terminal autoinhibitory ...

    The type II p21-activated kinases (PAKs) are key effectors of RHO-family GTPases involved in cell motility, survival, and proliferation. Using a structure-guided approach, we discovered that type II PAKs are regulated by an N-terminal autoinhibitory pseudosubstrate motif centered on a critical proline residue, and that this regulation occurs independently of activation loop phosphorylation. We determined six X-ray crystal structures of either full-length PAK4 or its catalytic domain, that demonstrate the molecular basis for pseudosubstrate binding to the active state with phosphorylated activation loop. We show that full-length PAK4 is constitutively autoinhibited, but mutation of the pseudosubstrate releases this inhibition and causes increased phosphorylation of the apoptotic regulation protein Bcl-2/Bcl-X(L) antagonist causing cell death and cellular morphological changes. We also find that PAK6 is regulated by the pseudosubstrate region, indicating a common type II PAK autoregulatory mechanism. Finally, we find Src SH3, but not β-PIX SH3, can activate PAK4. We provide a unique understanding for type II PAK regulation.


    Organizational Affiliation

    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Serine/threonine-protein kinase PAK 4AB423Homo sapiensMutation(s): 0 
Gene Names: KIAA1142PAK4
EC: 2.7.11.1
Find proteins for O96013 (Homo sapiens)
Explore O96013 
Go to UniProtKB:  O96013
NIH Common Fund Data Resources
PHAROS  O96013
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ANP
Query on ANP

Download CCD File 
A, B
PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER
C10 H17 N6 O12 P3
PVKSNHVPLWYQGJ-KQYNXXCUSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
A,BL-PEPTIDE LINKINGC3 H8 N O6 PSER
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.11 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.256 
  • R-Value Observed: 0.257 
  • Space Group: P 3
  • Diffraction Data DOI: 10.15785/SBGRID/433 SBGrid
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 141.537α = 90
b = 141.537β = 90
c = 61.893γ = 120
Software Package:
Software NamePurpose
Executordata collection
PHASERphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2012-06-08 
  • Released Date: 2012-09-12 
  • Deposition Author(s): Ha, B.H., Boggon, T.J.

Revision History 

  • Version 1.0: 2012-09-12
    Type: Initial release
  • Version 1.1: 2012-09-26
    Changes: Database references
  • Version 1.2: 2012-10-31
    Changes: Database references